Bristol-Myers Squibb Company (BMY)
Symbol Info
Listed Symbol BMY
Name Bristol-Myers Squibb Company
Share Info
Annual Info
Latest Fiscal Dividend Per Share $1.61
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $21,581,000,000
Latest Fiscal EPS $3.01
Price Info
21 Day Moving Average $50.6213
21 Day EMA $50.751440
50 Day Moving Average $48.9094
50 Day EMA $49.235660
200 Day EMA $48.409300
200 Day Moving Average 47.214470
52 Week High $55.85
52 Week Low $42.48
52 Week Change $-2.010800
Alpha -0.001539
Beta 0.6807
Standard Deviation 0.071007
R2 0.108376
Periods 60
Share Information
10 Day Average Volume 9,282,626
20 Day Average Volume 9,833,025
30 Day Average Volume 9,501,360
50 Day Average Volume 9,748,207
Outstanding Shares 1,635,766,530
Float Shares 1,629,264,495
Percent Float 99.60%
Short Interest 149,506,045
Short Percent Float 9.10%
Short Interest Ratio 16.54
Short Date 2019-09-30
Holders
Institutions 3,008
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 335,126,854
Institute Holdings Percent -
Institute Sold Previous 3 Months 161,500,060
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 11
Insider Holdings Percent 0.40%
Insider Sold Previous 3 Months 1
Insiders Shares Owned 6,502,035
Price Change
7 Day Price Change $1.4199982
7 Day Percent Change 2.75%
21 Day Price Change $3.2284317
21 Day Percent Change 6.48%
30 Day Price Change $3.5854340
30 Day Percent Change 7.25%
Month To Date Price Change $2.7425
Month To Date Percent 5.45%
90 Day Price Change $9.347023
90 Day Percent Change 21.40%
Quarter To Date $2.742516
Quarter To Date Percent 5.45%
180 Day Price Change $8.285740
180 Day Percent Change 18.52%
200 Day Price Change $7.147327
200 Day Percent Change 15.58%
Year To Date $2.778767
Year To Date Percent 5.53%
Profile
Description Bristol-Myers Squibb Co discovers, develops, and markets drugs for various indications, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs.
Details
Issue Type CS
Market Cap $86,744,699,086
Sec Type EQS
Auditor Deloitte & Touche LLP
Total Shares Outstanding 1,635,766,530
CEO Giovanni Caforio
Employees 23,300
Last Audit UQ
Classification
CIK 0000014272
Industry Drug Manufacturers
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 430 East 29th Street
14th Floor
New York, NY 10016
Website http://www.bms.com
Facisimile
Telephone +1 212 546-4000
Email john.elicker@bms.com
Key Ratios
Profitability
EBIT Margin 32.20
EBITDA Margin 35.1
Pre-Tax Profit Margin 21.8
Profit Margin Cont 24.70
Gross Margin 69.90
Profit Margin TOT 24.70
Income Statements
Revenue $17,459,000,000
Revenue Per Share $10.6733
Revenue 3 Years $4.07
Revenue 5 Years $11.95
Valuation Measures
PE Ratio 13.00
Enterprise Value $53,592,720,736
Price To Sales 4.968480
Price To Free Cash 21.100000
PE High Last 5 Years 116.8
Price To Book 5.0
Price To Cash Flow 11.2
PE Low Last 5 Years 17.4
Price To Tangible Book 9.5
Financial Strength
Total Debt To Equity 1.6
Int Coverage 29.6
Current Ratio 3.9
Leverage Ratio 2.9
Quick Ratio 3.6
Long Term Debt To Capital 0.60
Assets
Receivables Turnover 1.2
Invoice Turnover 5.50
Assets Turnover 0.20
Management Effectiveness
Return Assets 14.13
Return On Equity 43.74
Return On Capital 21.03
Dividends
Dividend 3 Years $3.22
Dividend 5 Years $-0.02
Ex Dividend Date 2019-10-03 00:00:00.0
Dividend Rate $1.64
Dividend Yield 3.09%
Payment Type Cash


Your Recent History
NYSE
BMY
Bristol My..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.